Navidea biopharmaceuticals announces acceptance of therapeutics focused abstract for presentation at the frontiers in cancer immunotherapy symposium

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the results from the company's preclinical studies of its targeted cancer immunotherapeutic agent will be presented as a poster at the new york academy of science's (nyas) frontiers in cancer immunotherapy symposium 2021. the poster is titled, “targeted delivery o
NAVB Ratings Summary
NAVB Quant Ranking